These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26709239)

  • 1. Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms.
    Kaltenborn A; Matzke S; Kleine M; Krech T; Ramackers W; Vondran FW; Klempnauer J; Bektas H; Schrem H
    J Surg Oncol; 2016 Feb; 113(2):194-202. PubMed ID: 26709239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.
    Cherenfant J; Talamonti MS; Hall CR; Thurow TA; Gage MK; Stocker SJ; Lapin B; Wang E; Silverstein JC; Mangold K; Odeleye M; Kaul KL; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA
    Surgery; 2014 Dec; 156(6):1504-10; discussion 1510-1. PubMed ID: 25456943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
    Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
    Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
    Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
    World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
    Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
    Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis.
    Gaitanidis A; Patel D; Nilubol N; Tirosh A; Sadowski S; Kebebew E
    Ann Surg Oncol; 2018 Jan; 25(1):122-130. PubMed ID: 29134377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
    Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
    Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
    Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
    Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
    J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.